Clinical Trials Browser

Metastatic Digestive System Neuroendocrine Tumor G1

Advanced Lung Neuroendocrine Tumor

Thymus Neoplasms, Neuroendocrine Tumors

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

Kidney Neoplasms, Neuroendocrine Tumors

Neuroendocrine Tumors

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

Carcinoma, Hepatocellular, Neoplastic Cells, Circulating, Neuroendocrine Tumors

Lymphoma, Follicular, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Neuroendocrine Tumors

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

Neuroendocrine Tumors

Liver Neoplasms, Neuroendocrine Tumors

Metatropic dwarfism, Neuroendocrine Tumors

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Liver Neoplasms, Neuroendocrine Tumors

Carcinoma, Neoplasms, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Neuroendocrine Tumors

Carcinoid Tumor, Neuroendocrine Tumors

Clinical Trials

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

LEVEL

STELLAR-311

Sapu003 in Advanced mTOR-sensitive Solid Tumors

ACTION-1

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

COMPOSE

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

COMPETE

SEQTOR

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

EVACEL

EVENET

Study of Everolimus (RAD001) in Combination With Lenalidomide

RADIANT-4

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Circulating Tumor Cells and Tumor DNA in HCC and NET

EVINEC

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

RAMSETE/CDE16

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

COOPERATE-2

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

NETPET

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor